Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: Critical roles of IFNγ
Srabanti Rakshit
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorManikandan Ponnusamy
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorSumitha Papanna
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorBanishree Saha
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorAsma Ahmed
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorCorresponding Author
Dipankar Nandi
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Tel: +91-80-2293-3051, Fax: +91-80-2360-0814
Department of Biochemistry, IISc, Bangalore, Karnataka 560012, IndiaSearch for more papers by this authorSrabanti Rakshit
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorManikandan Ponnusamy
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorSumitha Papanna
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorBanishree Saha
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorAsma Ahmed
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Search for more papers by this authorCorresponding Author
Dipankar Nandi
Department of Biochemistry, Indian Institute of Science (IISc), Bangalore, Karnataka, India
Tel: +91-80-2293-3051, Fax: +91-80-2360-0814
Department of Biochemistry, IISc, Bangalore, Karnataka 560012, IndiaSearch for more papers by this authorAbstract
Mycobacterium indicus pranii (MIP) is approved for use as an adjuvant (Immuvac/Cadi-05) in the treatment of leprosy. In addition, its efficacy is being investigated in clinical trials on patients with tuberculosis and different tumors. To evaluate and delineate the mechanisms by which autoclaved MIP enhances anti-tumor responses, the growth of solid tumors consisting of Sp2/0 (myeloma) and EL4 (thymoma) cells was studied in BALB/c and C57BL/6 mice, respectively. Treatment of mice with a single intra-dermal (i.d.) injection of MIP 3 days after Sp2/0 implantation greatly suppresses tumor growth. MIP treatment of tumor bearing mice lowers Interleukin (IL)6 but increases IL12p70 and IFNγ amounts in sera. Also, increase in CD8+ T cell mediated lysis of specific tumor targets and production of high amounts of IL2 and IFNγ by CD4+ T cells upon stimulation with specific tumor antigens in MIP treated mice is observed. Furthermore, MIP is also effective in reducing the growth of EL4 tumors; however, this efficacy is reduced in Ifnγ−/− mice. In fact, several MIP mediated anti-tumor responses are greatly abrogated in Ifnγ−/− mice: increase in serum Interleukin (IL)12p70 amounts, induction of IL2 and lysis of EL4 targets by splenocytes upon stimulation with specific tumor antigens. Interestingly, tumor-induced increase in serum IL12p70 and IFNγ and reduction in growth of Sp2/0 and EL4 tumors by MIP are not observed in nonobese diabetic severe combined immunodeficiency mice. Overall, our study clearly demonstrates the importance of a functional immune network, in particular endogenous CD4+ and CD8+ T cells and IFNγ, in mediating the anti-tumor responses by MIP.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| IJC_26099_sm_SuppInfo.doc787 KB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008; 26: 4984–90.
- 2 Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009; 28: 345–53.
- 3 Stanford JL, Stanford CA, Grange JM. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9: 1701–19.
- 4 Maraveyas A, Baban B, Kennard D, Rook GA, Westby M, Grange JM, Lydyard P, Stanford JL, Jones M, Selby P, Dalgleish AG. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999; 10: 817–24.
- 5 O'Brien ME, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, Von Pawel J, Reck M. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 2004; 15: 906–14.
- 6 Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, et al. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 2008; 44: 216–23.
- 7 Stanford JL, Stanford CA, O'Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008; 44: 224–7.
- 8 Talwar GP. Towards development of a vaccine against leprosy. Introduction. Lepr India 1978; 50: 492–7.
- 9 Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, Hasnain SE, Tyagi AK, Tyagi AK. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS One 2009; 4: e6263.
- 10 Zaheer SA, Mukherjee R, Ramkumar B, Misra RS, Sharma AK, Kar HK, Kaur H, Nair S, Mukherjee A, Talwar GP. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 1993; 167: 401–10.
- 11 Sharma P, Mukherjee R, Talwar GP, Sarathchandra KG, Walia R, Parida SK, Pandey RM, Rani R, Kar H, Mukherjee A, Katoch K, Benara SK, et al. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8–10 years. Lepr Rev 2005; 76: 127–43.
- 12 Singh IG, Mukherjee R, Talwar GP. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w. Vaccine 1991; 9: 10–14.
- 13 Gupta A, Geetha N, Mani J, Upadhyay P, Katoch VM, Natrajan M, Gupta UD, Bhaskar S. Immunogenicity and protective efficacy of “Mycobacterium w” against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immun 2009; 77: 223–31.
- 14 Katoch K, Singh P, Adhikari T, Benara SK, Singh HB, Chauhan DS, Sharma VD, Lavania M, Sachan AS, Katoch VM. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 2008; 26: 1228–34.
- 15 Kharkar R. Immune recovery in HIV with Mycobacterium w. J Indian Med Assoc 2002; 100: 578–9.
- 16 Rath N, Kar HK. Efficacy of intra dermal heat-killed Mycobacterium w in psoriasis: a pilot study. Int J Dermatol 2003; 42: 756–7.
- 17 Sur PK, Dastidar AG. Role of Mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer). J Indian Med Assoc 2003; 101: 118–20.
- 18 Chaudhuri P, Mukhopadhyay S. Bladder preserving approach for muscle invasive bladder cancer—role of Mycobacterium w. J Indian Med Assoc 2003; 101: 559–60.
- 19 Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324–39.
- 20 Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: a focus on current therapeutic management. J Thorac Oncol 2009; 4: 119–26.
- 21 Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157–65.
- 22 Imada K. Immunodeficient mouse models of lymphoid tumors. Int J Hematol 2003; 77: 336–41.
- 23 Prasanna SJ, Nandi D. The MHC-encoded class I molecule, H-2Kk, demonstrates distinct requirements of assembly factors for cell surface expression: roles of TAP, Tapasin and beta2-microglobulin. Mol Immunol 2004; 41: 1029–45.
- 24 Lamchouri F, Settaf A, Cherrah Y, Zemzami M, Lyoussi B, Zaid A, Atif N, Hassar M. Antitumour principles from Peganum harmala seeds. Therapie 1999; 54: 753–8.
- 25 Ahmed A, Mukherjee S, Nandi D. Intracellular concentrations of Ca2+ modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte antigen-4 (CD152)-CD80/CD86 interactions in CD4+ T lymphocytes. Immunology 2009; 126: 363–77.
- 26 Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11–22.
- 27 Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest 2003; 111: 595–7.
- 28 Matsumoto M, Seya T, Kikkawa S, Tsuji S, Shida K, Nomura M, Kurita-Taniguchi M, Ohigashi H, Yokouchi H, Takami K, Hayashi A, Azuma I, et al. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol 2001; 1: 1559–69.
- 29 Riemensberger J, Böhle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002; 127: 20–6.
- 30 Flacher V, Sparber F, Tripp CH, Romani N, Stoitzner P. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother 2009; 58: 1137–47.
- 31 Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, Tanguy M, Fiette L, Saeland S, Gicquel B, Winter N. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 2005; 106: 1843–50.
- 32 Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, Adema GJ. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 2009; 4: e8368.
- 33 Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 371–83.
- 34 Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000; 13: 265–76.
- 35 Guleria I, Mukherjee R, Kaufmann SH. In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tuberculosis in mice. Med Microbiol Immunol 1993; 182: 129–35.
- 36 Singh IG, Mukherjee R, Talwar GP, Kaufmann SH. In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infect Immun 1992; 60: 257–63.
- 37 Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002; 16: 1182–8.
- 38 Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, Hamaoka T. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol 1997; 62: 450–7.
- 39 Lee NC, Tsung K, Norton JA. Production of interferon-gamma by tumor-sensitized T cells is essential for interleukin-12-induced complete tumor eradication. Surgery 2002; 132: 365–8.
- 40 Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, Tomura M, Ono S, Tsujimura T, Fujiwara H, Hamaoka T. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res 2001; 61: 3399–405.
- 41 Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y. Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 2002; 105: 92–100.
- 42 Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010; 50: 1–14.
- 43 Rezai MS, Khotaei G, Mamishi S, Kheirkhah M, Parvaneh N. Disseminated Bacillus Calmette-Guerin infection after BCG vaccination. J Trop Pediatr 2008; 54: 413–16.
Citing Literature
